Reaction

Rehabilitation Therapy reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,808 reports · 85 co-occurring drugs

As of the last recalculation, Rehabilitation Therapy appears in 3,808 FAERS reports alongside 85 co-occurring drug terms. The strongest observed disproportionality signal is CARBIDOPA AND LEVODOPA (PRR 31.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Carbidopa And Levodopa	256	31.5	31.7
Cinacalcet Hydrochloride	203	25.1	25.2
Amikacin	72	23.5	23.6
Amantadine	51	18.3	18.3
Rasagiline Mesylate	32	15.8	15.9
Rotigotine	35	13.3	13.4
Patiromer	33	13.1	13.2
Rivastigmine	42	12.3	12.3
Ropinirole	30	10.8	10.8
Macitentan	129	10.5	10.5
Riociguat	59	10.0	10.0
Levodopa	22	10.0	10.0
Fluticasone Propionate And Salmeterol	74	9.9	9.9
Ibrutinib	138	9.7	9.7
Selexipag	40	8.5	8.6
Pramipexole	22	7.9	7.9
Umeclidinium	12	7.3	7.4
Risankizumab-Rzaa	107	7.3	7.3
Darbepoetin Alfa	71	7.3	7.3
Donepezil Hydrochloride	48	7.2	7.2
Esketamine Hydrochloride	23	7.1	7.1
Fluticasone Furoate And Vilanterol Trifenatate	46	7.1	7.1
Venetoclax	76	6.9	6.9
Alemtuzumab	23	6.5	6.5
Umeclidinium Bromide And Vilanterol Trifenatate	19	6.2	6.2
Memantine	15	6.0	6.0
Memantine Hydrochloride	15	6.0	6.0
Mirabegron	41	5.8	5.8
Upadacitinib	83	5.7	5.7
Fluticasone Propionate And Salmeterol Xinafoate	61	5.6	5.6
Brivaracetam	9	5.5	5.5
Romosozumab-Aqqg	13	5.2	5.3
Polyethylene Glycol	10	5.1	5.1
0Xygen	45	5.0	5.0
Oxygen	45	5.0	5.0
Glecaprevir And Pibrentasvir	10	5.0	5.0
Pimavanserin Tartrate	49	4.9	4.9
Rifaximin	18	4.7	4.7
Melatonin	46	4.7	4.7
Epoprostenol	11	4.6	4.6
Cenobamate	7	4.6	4.6
Thiamine Hydrochloride, Riboflavin 5 Phosphate Sodium, Dexpanthenol And Niacinamide	25	4.5	4.5
Metolazone	9	4.4	4.4
Naltrexone	24	4.3	4.3
Apalutamide	9	4.2	4.2
Vibegron	6	4.1	4.1
Hydrocodone Bitartrate And Acetaminophen	38	3.7	3.7
Pancrelipase	26	3.7	3.7
Teriflunomide	30	3.6	3.6
Romiplostim	10	3.6	3.6
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	27	3.6	3.6
Cariprazine	6	3.5	3.5
Sildenafil	37	3.5	3.5
Adalimumab	388	3.2	3.2
Clozapine	71	3.1	3.1
Eltrombopag Olamine	13	3.1	3.1
Prochlorperazine Maleate	5	3.0	3.0
Sevelamer Carbonate	6	2.9	2.9
Lacosamide	19	2.8	2.8
Droxidopa	11	2.8	2.8
Oxycodone Hydrochloride	106	2.7	2.7
Budesonide, Glycopyrrolate, And Formoterol Fumarate	5	2.6	2.6
Linaclotide	12	2.5	2.5
Nintedanib	14	2.4	2.4
Bosentan	21	2.3	2.3
Teriparatide	43	2.1	2.1
Ranolazine	4	2.1	2.1
Denosumab	75	2.0	2.0
Ravulizumab	5	2.0	2.0
Pazopanib Hydrochloride	10	2.0	2.0
Oral Semaglutide	27	2.0	2.0
Abiraterone	5	2.0	2.0
Brexpiprazole	6	2.0	2.0
Paliperidone Palmitate	11	1.9	1.9
Dalfampridine	24	1.8	1.8
Elexacaftor, Tezacaftor, And Ivacaftor	4	1.8	1.8
Ambrisentan	35	1.5	1.5
Abiraterone Acetate	11	1.5	1.5
Evolocumab	42	1.4	1.4
Leuprolide Acetate	20	1.4	1.4
Abaloparatide	7	1.3	1.3
Relugolix	5	1.2	1.2
Voxelotor	4	1.0	1.0
Valbenazine	4	0.9	0.9
Apremilast	19	0.7	0.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.